Biomarin Pharmaceutical Inc (BMRN)

99.42
NASDAQ : Health Care
Prev Close 98.20
Day Low/High 96.17 / 99.62
52 Wk Low/High 62.12 / 148.30
Avg Volume 1.67M
Exchange NASDAQ
Shares Outstanding 162.32M
Market Cap 15.94B
EPS -1.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Roche Beats First-Half Forecasts as Cancer Drug Sales Rise

Roche Beats First-Half Forecasts as Cancer Drug Sales Rise

The Swiss pharmaceuticals company confirms a forecast for full-year sales to increase in the low to mid-single digits, and for earnings per share to grow faster than revenue.

3 Stocks Driving The Drugs Industry Higher

3 Stocks Driving The Drugs Industry Higher

TheStreet highlights 3 stocks pushing the drugs industry higher today.

Cramer: 11 Reasons Why the Market Turned

Cramer: 11 Reasons Why the Market Turned

All of these add up to a level of insecurity on the part of sidelined money.

Biomarin Pharmaceutical (BMRN) Highlighted As Storm The Castle Stock

Biomarin Pharmaceutical (BMRN) Highlighted As Storm The Castle Stock

Trade-Ideas LLC identified Biomarin Pharmaceutical (BMRN) as a "storm the castle" (crossing above the 200-day simple moving average on higher than normal relative volume) candidate

Closing Bell: Humana Slumps on Deal Worries; U.S. Stocks Mixed

Closing Bell: Humana Slumps on Deal Worries; U.S. Stocks Mixed

A sharp selloff in crude kept stocks mostly in the red, though optimism ahead of Friday's jobs reports kept losses to a minimum on Thursday.

BioMarin (BMRN) Stock Soars on Takeover Speculation

BioMarin (BMRN) Stock Soars on Takeover Speculation

BioMarin (BMRN) stock is trading sharply higher this morning following reports that Roche (RHHBY) could pursue a takeover.

Biomarin Pharmaceutical (BMRN) Trading With Heavy Volume Before Market Open

Biomarin Pharmaceutical (BMRN) Trading With Heavy Volume Before Market Open

Trade-Ideas LLC identified Biomarin Pharmaceutical (BMRN) as a pre-market mover with heavy volume candidate

Medivation Tries to Prove Its Worth

Medivation Tries to Prove Its Worth

A call with investors Wednesday highlights drugs in the pipeline that could be attractive to bidders that reportedly include Sanofi, Pfizer and Celgene, among others.

Trade-Ideas: Biomarin Pharmaceutical (BMRN) Is Today's Post-Market Leader Stock

Trade-Ideas: Biomarin Pharmaceutical (BMRN) Is Today's Post-Market Leader Stock

Trade-Ideas LLC identified Biomarin Pharmaceutical (BMRN) as a post-market leader candidate

Biotech Stock Mailbag: Mid-Year Assessment, Where We Go From Here

Biotech Stock Mailbag: Mid-Year Assessment, Where We Go From Here

TheStreet's Adam Feuerstein answers reader questions about biotech stocks.

16 Biopharma Companies Besides Medivation That Are Attractive Targets

16 Biopharma Companies Besides Medivation That Are Attractive Targets

Besides Sanofi, Biogen is the next most likely to complete a sizable transaction in the next 12 months, according to Credit Suisse analysts.

RBC sees biopharma 'insulated' from Brexit, says buy Celgene for bounceback

RBC sees biopharma 'insulated' from Brexit, says buy Celgene for bounceback

The U.S. woke up today to the news of a "Brexit" win, which has sent global markets reeling.

BioMarin Announces Acceptance Of Late Breaking Abstract For BMN 270 At The World Federation Of Hemophilia (WFH) 2016 World Congress July 27 In Orlando, FL

BioMarin Announces Acceptance Of Late Breaking Abstract For BMN 270 At The World Federation Of Hemophilia (WFH) 2016 World Congress July 27 In Orlando, FL

Investor event to be held in Orlando following the July 27 oral presentation at the WFH meeting

BioMarin Pharmaceuticals Jumps on Takeover Talk

BioMarin Pharmaceuticals Jumps on Takeover Talk

Biotech company BioMarin Pharmacuetical's shares are moving sharply higher on heavy volume in Friday's session.

BioMarin Takeout Rumors Swirl, Industry Insiders Aren't Convinced

BioMarin Takeout Rumors Swirl, Industry Insiders Aren't Convinced

While some say Sanofi could make a bid for BioMarin, analysts aren't so convinced.

Why BioMarin (BMRN) Stock Is Lower Today

Why BioMarin (BMRN) Stock Is Lower Today

BioMarin (BMRN) stock is falling this afternoon after after the company suspended recruitment for a drug trial, but Evercore contends that investors are overreacting.

3 Drugs Stocks Driving The Industry Higher

3 Drugs Stocks Driving The Industry Higher

TheStreet highlights 3 stocks pushing the drugs industry higher today.

Biomarin Pharmaceutical (BMRN) Is Today's Strong On High Volume Stock

Biomarin Pharmaceutical (BMRN) Is Today's Strong On High Volume Stock

Trade-Ideas LLC identified Biomarin Pharmaceutical (BMRN) as a strong on high relative volume candidate

3 Stocks Dragging In The Health Care Sector

3 Stocks Dragging In The Health Care Sector

TheStreet highlights 3 stocks pushing the health care sector lower today.

3 Health Care Stocks Pushing Sector Growth

3 Health Care Stocks Pushing Sector Growth

TheStreet highlights 3 stocks pushing the health care sector higher today.

Insider Trading Alert - SUM, KLXI And BMRN Traded By Insiders

Insider Trading Alert - SUM, KLXI And BMRN Traded By Insiders

Stocks with insider trader activity include SUM, KLXI and BMRN

The New #24 Most Shorted Nasdaq 100 Component: BioMarin Pharmaceutical

The New #24 Most Shorted Nasdaq 100 Component: BioMarin Pharmaceutical

The most recent short interest data has been released for the 05/13/2016 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

A 'What's Next?' Scenario for the Delayed Sarepta Duchenne Drug Review

A 'What's Next?' Scenario for the Delayed Sarepta Duchenne Drug Review

If you take the easy approve/reject eteplirsen options off the table (and the delay certainly indicates FDA can't make up its mind) then a compromise decision is a possibility.